DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Tofacitinib (Xeljanz) (Rheumatoid Arthritis) (Wave 2) 2013

This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA).
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products at one month, three months, six months and one year post launch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products.

Questions Answered in This Report:

  • Evaluate awareness (aided/unaided), interest, and initial reaction to XELJANZ

  • Identify the expected placement of XELJANZ in physicians’ treatment algorithm for RA
    - How will it compete against the biologic agents?
    - Which class of biologic agents will be affected more—TNF inhibitors or the alternate mechanism of action agents?
    - How many biologic failures will it take for a physician to initiate XELJANZ treatment?

  • Track the trial, adoption and usage of XELJANZ, including anticipated future trends
    - What are the obstacles to growth for XELJANZ?

  • Determine what messages (and counter messages) are being delivered for XELJANZ
    - How will the product be positioned against the biologics?

  • Quantify the proportion of rheumatologists who have prescribed XELJANZ and at what point non-prescribers will begin initiating trial


Sample Frame & Methodology:

30-45 minute online survey with 75+ rheumatologists for Waves 1-3 100 rheumatologists for Wave 4

A subset of 15 rheumatologists per wave participate in qualitative interviews

- In practice for at least 2 years and no more than 30 years

- Minimum of 50 biologic treated RA patients under their personal management

- > 75% of time spent in clinical practice


PowerPoint decks to be published for each of four waves

Complete set of frequency tables, summary statistics, and cross tabulations

Up to three proprietary questions answered per client

Product Coverage:

Actemra, Cimzia, Enbrel, Humira, Orencia IV / SC, Remicade, Rituxan, Simponi, Xeljanz

Related 2013 Reports:

TreatmentTrends®: RA (US)

TreatmentTrends®: RA (EU)

ChartTrends®: RA (US)

ChartTrends®: RA (EU)

PatientTrends®: RA (US)

Treatment Algorithms: RA